Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisine vs NRT for Tobacco Dependence in the Systemically Disadvantaged Population
NCT03249428Enrolling by invitation
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Nov 2025
- Primary completion
- Mar 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of cytisinicline in tobacco dependence (2 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoint: Overall Quality of Life at 13 weeks. Started Nov 2025; status: enrolling by invitation.
02
Drugs
cytisinicline
03
Conditions
tobacco dependence
Beyond the preview
Go deeper on NCT03249428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03249428.